NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life.

Age and performance status in the prediction of CDDI and toxicity Age demonstrated no prognostic value for CDDI ( P =0.62), although performance status (PS) showed a slight trend towards PS 2 patients achieving a lower median CDDI (85% (IQR=65–94) ( P =0.07)).

also in 4,078 other papers

With a median follow-up of 4 years, NEAT showed a highly significant 28% advantage in RFS and 30% advantage in OS, with these advantages increasing to 31 and 33%, respectively, when analysed in a meta-analysis with the BR9601 trial ( Poole et al , 2006 ).

also in 132,142 other papers